{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:25:47Z","timestamp":1761488747859},"reference-count":33,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2011,8,11]],"date-time":"2011-08-11T00:00:00Z","timestamp":1313020800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>We screened tuberculosis (TB) contacts as an outbreak investigation with tuberculin skin test (TST) and interferon-gamma release assay (IGRA). We evaluated adverse events and TB incidence in all persons screened after rifampicin (RFP) prophylaxis, and specifically assessed the new TB cases in relation to initial TST and IGRA results. The 180 contacts were divided into four groups: TST+\/IGRA+ (<jats:italic>n<\/jats:italic>=101), TST+\/IGRA\u2212 (<jats:italic>n<\/jats:italic>=22), TST\u2212\/IGRA+ (<jats:italic>n<\/jats:italic>=16), and TST\u2013\/IGRA\u2013 (<jats:italic>n<\/jats:italic>=41). RFP treatment (4 months) was prescribed only to the TST+\/IGRA+ group. Of 87 contacts who initiated prophylaxis, adverse events occurred in 21 contacts (24\u00b71%) including hepatotoxicity (11\u00b75%), flu-like syndrome (5\u00b77%), and thrombocytopenia (3\u00b74%). TB developed in two TST+\/IGRA+ subjects after completion of prophylaxis, including one multidrug-resistant (MDR)-TB case during 21\u00b78 months of follow-up. Adverse events were frequent, and development of TB including MDR-TB occurred after RFP prophylaxis.<\/jats:p>","DOI":"10.1017\/s0950268811001476","type":"journal-article","created":{"date-parts":[[2011,8,11]],"date-time":"2011-08-11T10:02:04Z","timestamp":1313056924000},"page":"1028-1035","source":"Crossref","is-referenced-by-count":12,"title":["Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak"],"prefix":"10.1017","volume":"140","author":[{"given":"S. H.","family":"LEE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-J.","family":"YIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"KIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. S.","family":"SHIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. S.","family":"SEO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. S.","family":"CHO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-K.","family":"LEE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. M.","family":"LEE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. J.","family":"LEE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. J.","family":"LEW","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2011,8,11]]},"reference":[{"key":"S0950268811001476_ref025","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/3.2.115"},{"key":"S0950268811001476_ref010","first-page":"819","article-title":"Use of the QuantiFERON-TB Gold test for screening tuberculosis contacts and predicting active disease","volume":"14","author":"Yoshiyama","year":"2010","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"S0950268811001476_ref012","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1613OC"},{"key":"S0950268811001476_ref009","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-11-200812020-00248"},{"key":"S0950268811001476_ref022","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_3.S440"},{"key":"S0950268811001476_ref013","first-page":"675","article-title":"Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations","volume":"80","author":"Mori","year":"2005","journal-title":"Kekkaku"},{"key":"S0950268811001476_ref032","first-page":"571","article-title":"Trend of anti-tuberculosis drug resistance in Korea, 1994\u20132004","volume":"11","author":"Bai","year":"2007","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"S0950268811001476_ref029","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.155.5.9154885"},{"key":"S0950268811001476_ref016","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"S0950268811001476_ref019","doi-asserted-by":"publisher","DOI":"10.3201\/eid1205.050681"},{"key":"S0950268811001476_ref028","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.1.36"},{"key":"S0950268811001476_ref020","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.10.006"},{"key":"S0950268811001476_ref006","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"S0950268811001476_ref003","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.677"},{"key":"S0950268811001476_ref018","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1985.03350430059025"},{"key":"S0950268811001476_ref014","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-10-200811180-00003"},{"key":"S0950268811001476_ref005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp021045"},{"key":"S0950268811001476_ref017","first-page":"301","article-title":"A review of blood dyscrasias induced by the antituberculosis drugs","volume":"68","author":"Holdiness","year":"1987","journal-title":"Tubercle and lung disease"},{"key":"S0950268811001476_ref015","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-478OC"},{"key":"S0950268811001476_ref024","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199911000-00001"},{"key":"S0950268811001476_ref021","unstructured":"21. Korea Center for Disease Control. National guidelines for managing tuberculosis. KCDC guideline 2007, pp. 133\u2013141."},{"key":"S0950268811001476_ref007","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-5-200703060-00006"},{"key":"S0950268811001476_ref031","first-page":"431","article-title":"Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees","volume":"133","author":"Nolan","year":"1986","journal-title":"American Review of Respiratory Disease"},{"key":"S0950268811001476_ref033","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1513"},{"key":"S0950268811001476_ref027","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2010.01751.x"},{"key":"S0950268811001476_ref004","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00261402"},{"key":"S0950268811001476_ref026","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200303-390OC"},{"key":"S0950268811001476_ref002","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.9.1009"},{"key":"S0950268811001476_ref001","unstructured":"1. World Health Organization.The global plan to stop TB 2011\u20132015. Geneva: WHO, 2010. Report No. WHO\/HTM\/STB\/2010.2 (http:\/\/www.who.int\/tb\/publications\/2010\/eng.pdf). Accessed 3 January 2011."},{"key":"S0950268811001476_ref011","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00098509"},{"key":"S0950268811001476_ref030","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.5.8912767"},{"key":"S0950268811001476_ref008","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-3-200808050-00241"},{"key":"S0950268811001476_ref023","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5713.24"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268811001476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T16:57:45Z","timestamp":1556211465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268811001476\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0950268811001476"],"URL":"https:\/\/doi.org\/10.1017\/s0950268811001476","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,11]]}}}